HMGB1 Mediates Hepatic Ferroptosis and Fibrosis Triggered by Echinococcus granulosus Infection
This study demonstrates that High-mobility group box 1 (HMGB1) acts as a critical upstream regulator linking *Echinococcus granulosus* infection to hepatic injury by driving a cascade of inflammation, ferroptosis, and fibrosis, suggesting that targeting HMGB1 or ferroptosis offers a promising therapeutic strategy for cystic echinococcosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The liver is a resilient organ, but it is not invincible. When it is under constant assault, such as from a parasitic infection, it can become scarred and stiff, a condition known as fibrosis. This scarring happens because the body's attempt to wall off the invader goes into overdrive, laying down thick layers of collagen that eventually choke out healthy tissue. In recent years, scientists have discovered a specific way cells die called ferroptosis, which is essentially a rusting from the inside out. It occurs when a cell's internal defenses against iron and oxygen fail, causing the cell membrane to break apart. Another key player in this drama is a protein called HMGB1. Normally hidden inside the nucleus of a cell, this protein is released when a cell is damaged, acting like a distress signal that tells the immune system to attack and repair. The question researchers have long asked is how these different processes—the rusting of cells, the release of distress signals, and the formation of scars—are linked together during a chronic infection.
A team of researchers at Xinjiang Agricultural University set out to map this connection in the context of cystic echinococcosis, a disease caused by the tapeworm Echinococcus granulosus. This parasite is a significant health threat in many parts of the world, particularly in pastoral regions, where it forms fluid-filled cysts in the liver. The team wanted to know if the parasite's presence triggers a chain reaction where damaged liver cells release HMGB1, which then causes more cells to rust and die, ultimately leading to the severe scarring seen in infected patients. To find the answer, they looked at liver tissue from sheep that had naturally caught the infection, created a similar infection in rats, and studied liver cells in a laboratory dish.
The researchers began by examining the livers of sheep that had been infected with the parasite in the wild. They found that the livers were covered in cysts and surrounded by thick, fibrous walls. When they stained the tissue to look for iron, they saw that the liver cells near the cysts were packed with it, a sign of the rusting process known as ferroptosis. At the same time, they measured the levels of HMGB1 and found it was significantly higher in the infected sheep than in healthy ones. The data showed that the infection had disrupted the liver's ability to manage iron and protect itself from oxidative stress, creating an environment where cells were dying and scarring was forming.
To test whether this was a cause-and-effect relationship, the team turned to rats. They infected the animals with the parasite and then treated some of them with two different substances. One was a drug designed specifically to stop ferroptosis, and the other was glycyrrhizic acid, a compound known to block the release and activity of HMGB1. The results were clear. The rats that received no treatment developed large cysts and significant liver damage. However, the rats treated with either drug showed much less damage. Their livers had fewer cysts, less iron buildup, and far fewer signs of scarring. Interestingly, the treatment that blocked HMGB1 seemed to offer slightly broader protection, suggesting that this protein sits at the top of a chain reaction that drives the disease forward.
Digging deeper into the cells, the researchers discovered the mechanics of this chain. When liver cells were exposed to the parasite, they released HMGB1. This released protein then acted on nearby cells, making them more vulnerable to iron overload and cell death. In a laboratory setting, when the researchers added extra HMGB1 to healthy liver cells, those cells began to rust and die faster. Conversely, when they blocked HMGB1, the cells were protected. The study also showed that this released protein did not just hurt liver cells; it also woke up the liver's repair cells, known as stellate cells. Once activated, these stellate cells began producing the collagen that creates scars. The researchers found that blocking HMGB1 stopped this activation, preventing the formation of fibrous tissue.
The study concludes that the parasite does not just damage the liver directly; it triggers a self-perpetuating cycle of injury. The initial damage causes liver cells to release HMGB1, which in turn causes more cells to rust and die, while simultaneously signaling the body to lay down scar tissue. This cycle of inflammation, cell death, and scarring is what leads to the severe liver disease seen in advanced cases. By identifying HMGB1 as a central switch in this process, the researchers suggest that targeting this protein could be a new way to treat the disease, potentially stopping the damage before it becomes irreversible. While the study was conducted in animals and cells, the findings provide a clear roadmap for understanding how this parasitic infection destroys the liver and point toward a specific target for future therapies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.